FDA has granted orphan drug status to NTLA-2001, which is being developed by Intellia Therapeutics. It is designed to treat transthyretin amyloidosis. NTLA-2001 could be the first single-dose drug to treat this disease, as it has the potential to stop and reverse its devastating complications.